Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.

Autor:	De Greef J; Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Averbuch D; Pediatric Infectious Diseases, Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel., Tondeur L; Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, 75015 Paris, France., Duréault A; Centre d'Infectiologie Necker Pasteur, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université Paris Descartes, Paris, France., Zuckerman T; Rambam Health Care Campus, Haifa, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel., Roussel X; Department of Hematology, University of Franche-Comte, INSERM UMR1098, Besançon University Hospital, Besançon, France., Robin C; Department of Hematology, Henri Mondor University Hospital, Creteil, France., Xhaard A; Hematology-Transplantation, Hospital St-Louis, Paris Diderot University, Paris, France., Pagliuca S; Hematology Department, Nancy University Hospital, Vandoeuvre-lès-Nancy, France., Beguin Y; Centre Hospitalier Universitaire of Liège and University of Liège, Liège, Belgium., Botella-Garcia C; Centre Hospitalier Universitaire Bordeaux, Bordeaux, France., Khanna N; Division of Infectious Diseases and Hospital Epidemiology, University and University Hospital of Basel, Basel, Switzerland., Le Bourgeois A; Centre Hospitalier Universitaire Nantes, Nantes, France., Van Praet J; Department of Nephrology and Infectious Diseases, Algemeen Ziekenhuis Sint-Jan Brugge-Oostende, Brugge, Belgium., Ho A; Singapore General Hospital, Singapore., Kröger N; Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany., Ducastelle Leprêtre S; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France., Roos-Weil D; Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France., Aljurf M; King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia., Blijlevens N; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands., Blau IW; Campus Virchow Klinikum CVK, Berlin, Germany., Carlson K; Dept of Haematology, University Hospital, Uppsala, Sweden., Collin M; Nordern Centre for Bone Marrow Transplantation Freeman Hospital - Adult HSCT Unit, Newcastle, United Kingdom., Ganser A; Department of Hematology Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Villate A; Service d'hématologie et thérapie cellulaire, Centre Hospitalier Universitaire de Tours, Université de Tours, Tours, France., Lakner J; Medical Clinic III, University Medical Center, Rostock, Germany., Martin S; Robert-Bosch-Krankenhaus, Stuttgart, Germany., Nagler A; Chaim Sheba Medical Center, Tel Hashomer, Israel., Ram R; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Torrent A; ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain., Stamouli M; Attikon University General Hospital, Athens, Greece., Mikulska M; Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Gil L; European Society for Blood and Marrow Transplantation (EBMT), Leiden Study Unit, Leiden, the Netherlands., Wendel L; European Society for Blood and Marrow Transplantation (EBMT), Leiden Study Unit, Leiden, the Netherlands., Tridello G; European Society for Blood and Marrow Transplantation (EBMT), Leiden Study Unit, Leiden, the Netherlands., Knelange N; European Society for Blood and Marrow Transplantation (EBMT), Leiden Study Unit, Leiden, the Netherlands., de la Camara R; Hospital de la Princesa, Madrid, Spain; Infectious Diseases Working Party, EBMT, Spain., Lortholary O; Centre d'Infectiologie Necker Pasteur, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université Paris Descartes, Paris, France., Fontanet A; Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, 75015 Paris, France; Unité PACRI, Conservatoire National des Arts et Métiers, 75003 Paris, France., Styczynski J; Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland., Maertens J; Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium., Coussement J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia; Service de Maladies Infectieuses et Tropicales, Centre Hospitalier universitaire de Guadeloupe, Les Abymes, Guadeloupe, France. Electronic address: julien.coussement@chu-guadeloupe.fr., Lebeaux D; Institut Pasteur, Université Paris Cité, CNRS UMR 6047, Genetics of Biofilms Laboratory, 75015 Paris, France; Département de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Saint-Louis, Lariboisière, F-75010 Paris, France.
Jazyk:	angličtina
Zdroj:	The Journal of infection [J Infect] 2024 Jun; Vol. 88 (6), pp. 106162. Date of Electronic Publication: 2024 Apr 23.
DOI:	10.1016/j.jinf.2024.106162
Abstrakt:	Objectives: Nocardiosis is a rare but life-threatening infection after hematopoietic cell transplantation (HCT). We aimed at identifying risk factors for nocardiosis after allogeneic HCT and clarifying the effect of trimethoprim-sulfamethoxazole prophylaxis on its occurrence. Methods: We performed a retrospective multicenter case-control study of patients diagnosed with nocardiosis after allogeneic HCT between January 2000 and December 2018. For each case, two controls were matched by center, transplant date, and age group. Multivariable analysis was conducted using conditional logistic regression to identify potential risk factors for nocardiosis. Kaplan-Meier survival curves of cases and controls were compared using log-rank tests. Results: Sixty-four cases and 128 controls were included. Nocardiosis occurred at a median of 9 months after allogeneic HCT (interquartile range: 5-18). After adjustment for potential confounders in a multivariable model, Nocardia infection was associated with tacrolimus use (adjusted odds ratio [aOR] 9.9, 95 % confidence interval [95 % CI]: 1.6-62.7), lymphocyte count < 500/µL (aOR 8.9, 95 % CI: 2.3-34.7), male sex (aOR 8.1, 95 % CI: 2.1-31.5), recent use of systemic corticosteroids (aOR 7.9, 95 % CI: 2.2-28.2), and recent CMV infection (aOR 4.3, 95 % CI: 1.2-15.9). Conversely, use of trimethoprim-sulfamethoxazole prophylaxis was associated with a significantly decreased risk of nocardiosis (aOR 0.2, 95 % CI: 0.1-0.8). HCT recipients who developed nocardiosis had a significantly decreased survival, as compared with controls (12-month survival: 58 % and 90 %, respectively; p < 0.0001). Conclusions: We identified six factors independently associated with the occurrence of nocardiosis among allogeneic HCT recipients. In particular, trimethoprim-sulfamethoxazole prophylaxis was found to protect against nocardiosis. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect